Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 4, 2020

Primary Completion Date

October 21, 2020

Study Completion Date

November 2, 2020

Conditions
Acute Drug Induced Liver Injury
Interventions
DRUG

Polyene phosphatidylcholine injection 930 mg QD

Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.

DRUG

Magnesium Isoglycyrrhizinate injection 200 mg QD

Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.

Trial Locations (9)

Unknown

The Second Hospital of Anhui Medical University, Hefei

Beijing Chest Hospital of Capital Medical University, Beijing

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

Shenzhen People's Hospital, Shenzhen

The Sixth People's Hospital of Zhengzhou, Zhengzhou

The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang

Renji Hospital, Shanghai

Shanghai Pulmonary Hospital, Shanghai

Tongji Hospital, Shanghai

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04595916 - Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury | Biotech Hunter | Biotech Hunter